Christopher Verni
General Counsel at VIGIL NEUROSCIENCE, INC.
Net worth: 13 640 $ as of 31/03/2024
Profile
Christopher Verni is currently the General Counsel at Vigil Neuroscience, Inc. He previously worked as the Corporate Counsel-Intellectual Property at Pfizer Inc. from 2004 to 2007, as the Senior Patent Counsel at ARIAD Pharmaceuticals, Inc. from 2011 to 2013, and as the Chief Intellectual Property Officer & Senior VP at Sarepta Therapeutics, Inc. from 2013 to 2022.
Additionally, he served as the Senior Patent Counsel at Sanofi SA from 2007 to 2011.
Mr. Verni obtained his undergraduate degree from Rochester Christian University and his graduate degree from the University of New Hampshire School of Law.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
VIGIL NEUROSCIENCE, INC.
0.01% | 03/05/2024 | 4,000 ( 0.01% ) | 13 640 $ | 31/03/2024 |
Christopher Verni active positions
| Companies | Position | Start |
|---|---|---|
| VIGIL NEUROSCIENCE, INC. | General Counsel | 20/04/2022 |
Former positions of Christopher Verni
| Companies | Position | End |
|---|---|---|
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/04/2022 |
| ARIAD PHARMACEUTICALS, INC. | General Counsel | 01/11/2013 |
| Sanofi SA | General Counsel | 01/10/2011 |
| PFIZER, INC. | General Counsel | 01/05/2007 |
Training of Christopher Verni
| Rochester Christian University | Undergraduate Degree |
| University of New Hampshire School of Law | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| VIGIL NEUROSCIENCE, INC. | Health Technology |
| Private companies | 2 |
|---|---|
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
| Sanofi SA | Health Technology |
- Stock Market
- Insiders
- Christopher Verni